Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab in relapsed or refractory multiple myeloma
NL-OMON59020Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2019
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of talquetamab in multiple myeloma (MM) (5 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-limiting toxicities, Safety and laboratory abnormalities and 7 more. Started Feb 2019; status: active, not recruiting.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON59020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59020.